Most Read Articles
Pearl Toh, 15 Feb 2019
A latest study at ISC 2019 shows that even patients with large-core stroke damage can have a good outcome after mechanical clot removal with endovascular thrombectomy (EVT), depending on the size of the infarct and time lapses between stroke onset and treatment.
Stephen Padilla, 06 Feb 2019
Alirocumab has prevented nonfatal cardiovascular events and deaths, the total of which is twice the number of first events prevented among patients with acute coronary syndrome (ACS) over a median follow-up of 2.8 years, according to results of the ODYSSEY OUTCOMES* trial. In addition, a robust association is seen between the risks of nonfatal and fatal events during the study.
14 Sep 2017
Rifaximin appears to confer increased survival benefit in hepatic encephalopathy patients without hepatocellular carcinoma (HCC), in addition to reducing the risks of spontaneous bacterial peritonitis, variceal bleeding and recurrent hepatic encephalopathy, according to a study.
18 Jan 2019
Azithromycin treatment in children with recurrent asthma-like symptoms acutely disrupts gut microbiota composition, a recent study has found.

Oral–topical treatment regimen an attractive alternative to prednisone in bullous pemphigoid

27 Jan 2019

A treatment regimen containing oral tetracycline and nicotinamide plus topical clobetasol appears to be effective in the treatment of bullous pemphigoid (BP), yielding better survival rates compared with prednisone, according to a study.

The 3-year retrospective study included 106 patients with newly diagnosed BP (mean age 78 years; 64.4 percent female), among whom 59 received tetracycline 1.5 g/daily, nicotinamide 1.2 g/daily and 0.05 percent lesionally administered clobetasol cream (TNC arm), while 47 received prednisone 0.5 mg/kg daily.

Both patient groups achieved median time to disease control after 7 days. The proportion of patients who achieved disease control at week 4 was 93.2 percent in the TNC arm vs 89.1 percent in the prednisone arm.

The median period between complete remission and relapse was 60 days in the TNC group and 90 days in the prednisone group (p=0.84). Within 1 year, significantly more patients in the prednisolone vs TNC group had at least one relapse within 1 year (50 percent vs 32.1 percent; p=0.09).

The 1-year survival was 83 percent in the TNC group and 65.9 percent in the prednisone group (p=0.04), while the corresponding 3-year survival was 71.2 percent and 48 percent (p=0.019).

The present data show that combined treatment with tetracycline, nicotinamide and lesionally administered clobetasol may improve survival rates compared with prednisone in patients with BP, researchers said. Thus, it would be reasonable to initiate this regimen in age-advanced patients with comorbidities and movement difficulties.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 15 Feb 2019
A latest study at ISC 2019 shows that even patients with large-core stroke damage can have a good outcome after mechanical clot removal with endovascular thrombectomy (EVT), depending on the size of the infarct and time lapses between stroke onset and treatment.
Stephen Padilla, 06 Feb 2019
Alirocumab has prevented nonfatal cardiovascular events and deaths, the total of which is twice the number of first events prevented among patients with acute coronary syndrome (ACS) over a median follow-up of 2.8 years, according to results of the ODYSSEY OUTCOMES* trial. In addition, a robust association is seen between the risks of nonfatal and fatal events during the study.
14 Sep 2017
Rifaximin appears to confer increased survival benefit in hepatic encephalopathy patients without hepatocellular carcinoma (HCC), in addition to reducing the risks of spontaneous bacterial peritonitis, variceal bleeding and recurrent hepatic encephalopathy, according to a study.
18 Jan 2019
Azithromycin treatment in children with recurrent asthma-like symptoms acutely disrupts gut microbiota composition, a recent study has found.